28 March 2017 - - Growth in the global epilepsy and drugs market can be attributed to factors such as rising incidence of neurological disorders, growing disease awareness, introduction of novel antiepileptic drugs, strong government support and initiatives, according to a new report from Dublin-based Research and Markets.

Moreover, increasing R/D investment and launch of extended-release formulations are further expected to fuel the market growth.

However, high cost of patented drugs, concerns over decreasing healthcare costs as part of government austerity measures, particularly in Europe and low accessibility to antiepileptic drugs in low and middle income countries, are likely to restrict the market growth.

Vimpat is the undisputed leading drug of Global Epilepsy Drugs Market. It had a market share of nearly 22% in 2016 and is expected that Vimpat will gain its momentum till the forecasting period.

Keppra was the second highest market share taker with more than 19% share in 2016 but the prospect of this drug will change due to the patent expiration in 2018 and its share decline

It is expected that Lamictal will be the second leading drug by 2021.

Onfi will hold the third highest share of the Epilepsy Drugs market, being followed by Depakine by the year end of 2021.

The report concludes with the profiles of major players in the Epilepsy Drugs Market such as UCB, EISAI, Pfizer, Sanofi and Lundbeck. The major market players are evaluated on various parameters such as company overview and latest development and trends in the Epilepsy Drugs Market.